![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 39, 27457-27462, September 24, 1999
,
,From the Department of Cardiology, Medical University Hospital Heidelberg, Bergheimerstrasse 58, D-69115 Heidelberg, Germany
| |
ABSTRACT |
|---|
|
|
|---|
We investigated the role of protein kinase A
(PKA) in regulation of the human ether-a-go-go-related gene (HERG)
potassium channel activation. HERG clones with single mutations
destroying one of four consensus PKA phosphorylation sites (S283A,
S890A, T895A, S1137A), as well as one clone carrying all mutations with no PKA phosphorylation sites (HERG 4M) were
constructed. These clones were expressed heterologously in
Xenopus oocytes, and HERG potassium currents were measured
with the two microelectrode voltage clamp technique. Application of the
cAMP-specific phosphodiesterase (PDE IV) inhibitor Ro-20-1724 (100 µM), which results in an increased cAMP level and PKA
stimulation, induced a reduction of HERG wild type outward currents by
19.1% due to a shift in the activation curve of 12.4 mV. When 100 µM Ro-20-1724 was applied to the HERG 4M
channel, missing all PKA sites, there was no significant shift in the
activation curve, and the current amplitude was not reduced. Furthermore, the adenylate cyclase activator forskolin that leads to
PKA activation (400 µM, 60 min), shifted HERG wild type
channel activation by 14.1 mV and reduced currents by 39.9%, whereas
HERG 4M channels showed only a small shift of 4.3 mV and a
weaker current reduction of 22.3%. We conclude that PKA regulates HERG
channel activation, and direct phosphorylation of the HERG channel
protein has a functional role that may be important in regulation of
cardiac repolarization.
In cardiac myocytes, repolarization of the action potential is
produced by different potassium currents (1). Activation of the rapid
component of the delayed rectifier potassium current, IKr,1
initiates repolarization and terminates the plateau phase of the
cardiac action potential. The human ether-a-go-go-related gene (HERG)
(2) encodes the voltage-gated potassium channel underlying
IKr. This has been demonstrated in macroscopic
current measurements (3, 4) and single channel measurements (5). HERG
channels are one primary target for the pharmacological management of
arrhythmias with class III antiarrhythmic drugs:
IKr is blocked and the cardiac action potential
is prolonged (5-7). Mutations in HERG produce chromosome 7-linked
congenital long QT syndrome (LQT2) (3). These mutations are associated
with delayed cardiac repolarization, prolonged electrocardiographic QT
intervals (8), and a high risk for the development of ventricular
"torsade de pointes" arrhythmias and sudden cardiac death (9).
Cyclic AMP-dependent protein kinase (PKA) is a key enzyme
for numerous regulatory processes in almost all types of cells. It has
been demonstrated that PKA regulates ion channels in native tissue
(10). PKA is a serine/threonine kinase that can be stimulated by
extracellular signals that elevate intracellular cAMP concentrations. cAMP binds to the regulatory subunit of the enzyme, which leads to
dissociation of regulatory and catalytic subunits. The catalytic subunit phosphorylates the substrate at its specific phosphorylation sites. The substrate may either be the effector protein or another protein that mediates the effect. Increased cAMP concentrations can be
obtained experimentally with the adenylate cyclase activator forskolin
(11) and with the selective cAMP-specific phosphodiesterase (PDE IV)
inhibitor Ro-20-1724 (12).
Recently, we have demonstrated that PKA is involved in the regulation
of IKr in guinea pig cardiac myocytes and HERG
channels expressed heterologously in Xenopus oocytes (13).
Incubation of the cells with the phorbol ester phorbol 12-myristate
13-acetate (PMA) leads to a HERG current reduction due to a shift in
the activation curve that is mediated mainly by PKA. To investigate the
biochemical pathways of this regulation process in more detail, we
generated single mutations of all four PKA-specific phosphorylation sites in HERG, combined all of them, and expressed the resulting channel proteins in Xenopus oocytes. Because all enzymes
involved in the PKA cascade are present endogenously in
Xenopus oocytes, we could use indirect protein kinase A
activators and inhibitors to study the role of PKA in HERG channel regulation.
Our findings show that direct phosphorylation of the channel protein by
PKA is involved in the regulation of HERG channel activation, and the
PKA-mediated part of the shift in the HERG activation curve can be
abolished by mutating all PKA-specific phosphorylation sites in the
HERG channel protein.
Solutions and Drug Administration--
Voltage clamp
measurements of Xenopus oocytes were performed in a low
K+ solution containing (in mM) 5 KCl, 100 NaCl,
1.5 CaCl2, 2 MgCl2, and 10 HEPES (pH 7.3).
Current and voltage electrodes were filled with 3 M KCl solution.
Forskolin (Calbiochem) and Ro-20-1724 (Calbiochem) were dissolved in
Me2SO to a stock solution of 100 mM and stored
at Electrophysiology and Data Analysis--
The two-microelectrode
voltage-clamp configuration was used to record currents from
Xenopus laevis oocytes. Microelectrodes had tip resistances
ranging from 1 to 5 megaohms. Data were low-pass filtered at 1-2 kHz
( Site-directed Mutagenesis--
The HERG wild type (HERG WT)
clone (3) was a gift from M. T. Keating (GenBankTM
accession number hs04270), which contains the HERG potassium channel
coding region downstream the SP6 polymerase promotor. By use of
computer analysis with the program HUSAR PROSITE, we searched for
consensus PKA phosphorylation sites with the amino acid sequence
Arg-Lys-(2)-Xaa-Ser-Thr, where (2) means Arg-Arg and Lys-Lys are also
allowed. The program identified four sites. The serine or threonine
residues of the PKA phosphorylation sites (Ser-283, Ser-890, Thr-895,
Ser-1137) were replaced with the nonphosphorylatable alanine to
eliminate PKA-mediated phosphorylation at this position. This resulted
in the mutated channels HERG S283A, HERG S890A, HERG T895A, HERG
S1137A) The mutations were generated with polymerase chain reaction by
mutagenesis on the double-stranded plasmid using the QuickChange
site-directed mutagenesis kit (Stratagene, La Jolla, CA). The
polymerase chain reaction products between unique anchor sites were
sequenced (MWG-Biotech, Ebersberg, Germany), and fragments between
these unique restriction sites were cut out using the following
combinations of restriction enzymes: BstEII (1137) and
NcoI (668) for HERG S283A; FseI (2779) and
XhoI (2107) for HERG S890A and HERG T895A; BamHI
(3532) and FseI (2779) for HERG S1137A. The mutated
fragments were subcloned into the original HERG plasmid and sequenced again.
The HERG 4M clone (combination of all four mutations) was
generated by introducing mutation S890A into the T895A clone as described above, generating HERG S890A,T895A. Then the restriction fragments containing mutations S283A and S1137A were subcloned into
HERG S890A,T895A. Finally, cDNA of HERG 4M was verified
by DNA sequencing.
Expression of HERG Channels in Xenopus
Oocytes--
Complementary RNA was prepared from the corresponding
cDNA (HERG WT, HERG S283A, HERG S890A, HERG T895A, HERG S1137A,
HERG 4M) in the pSP64 transcription vector (Promega,
Madison, WI) with the mMESSAGE mMACHINE in vitro
transcription kit (Ambion, Austin, TX) by use of SP6 polymerase after
linearization with EcoRI (Roche Molecular Biochemicals).
Injection of RNA (50-500 ng/µl) into stage V and VI defolliculated
oocytes was performed by using a Nanoject automatic injector (Drummond,
Broomall, PA). The volume of injected cRNA solution was 46 nl/oocyte,
and measurements were made 2-10 days after injection.
Expression of HERG Channels with Deleted Consensus
Phosphorylation Sites for PKA--
We performed site-directed
mutagenesis of HERG to generate mutated channels that lack consensus
PKA phosphorylation sites (HERG S283A, HERG S890A, HERG T895A, HERG
S1137A; and in combination HERG 4M, see Fig.
1) and expressed these mutant channels in
Xenopus oocytes. All clones generated in this study resulted
in functional potassium channels with current kinetics similar to those
of HERG WT.
HERG Wild Type Channel Activation Curve Was Shifted by Increasing
cAMP Levels via Inhibition of the PDE IV--
To investigate the
effects of the PDE IV inhibitor Ro-20-1724 (IC50 = 2.2 µM) on HERG potassium channels, we measured currents using a two-step protocol (see Fig.
2A). A variable first step (test pulse) was applied at different potentials from Deletion of Phosphorylation Sites Inhibits the Activation Shift
Caused by PDE IV Inhibition in HERG 4M--
We mutated all
four consensus PKA phosphorylation sites in the HERG channel protein
(HERG 4M). The current kinetics of the HERG 4M
clone was almost identical to the wild type HERG channel current
kinetics (compare Figs. 3, A
and D with Fig. 2, A and D), but the
half-maximal activation voltage obtained during control measurements
was shifted toward more negative potentials (Fig. 3C). The
average V1/2 of HERG 4M during
control experiments was Elevation of cAMP Levels by Forskolin Leads to a Shift of the HERG
Channel Activation Curve--
To further elucidate the role of protein
kinase A in the HERG activation process in a different experimental
approach, we applied forskolin to the Xenopus oocytes
expressing HERG WT channels. Forskolin is an adenylate cyclase
activator (EC50 = 4.0 µM) that increases
intracellular cAMP levels and subsequently stimulates PKA. After having
obtained the control measurements (Fig.
4, A and D),
forskolin (400 µM) was perfused into the bath for 60 min. The resulting current traces are shown in Fig. 4, B and
E. Apparently, the activation curve was shifted, and the
maximum outward current during test pulses was reduced. In four
experiments V1/2 was shifted significantly by
14.1 ± 4.2 mV from 1.6 ± 2.0 mV to 15.7 ± 4.9 mV.
Currents were reduced by 39.9 ± 13.3% (n = 4).
Given the elevation of cAMP levels inside the oocyte by forskolin, this
demonstrates indirectly that PKA is a key enzyme for the described
activation shift.
Elevation of cAMP Levels by Forskolin Does not Shift the
Activation Curve of HERG 4M Channels--
To address the
question whether direct phosphorylation of the channel protein is
involved in the cascade of activation shift induced by forskolin, we
incubated HERG 4M with 0.4 mM forskolin. 60 min
after having recorded control current traces (Fig.
5, A and D), we
found only a small shift in the activation curve of 4.3 ± 1.6 mV
from HERG 4M Channel Baseline Activation Curves Are This study demonstrates that HERG potassium channel
activation is regulated by direct phosphorylation of the HERG protein. This has been shown by mutating all four consensus PKA phosphorylation sites in the HERG protein (resulting in the HERG 4M
channel) and analyzing the electrophysiological effects of PKA
stimulation by adding Ro-20-1724, an inhibitor of the PDE IV, or
adding the adenylate cyclase activator forskolin. Our results
demonstrated that the HERG wild type activation curve was shifted and
the repolarizing HERG current amplitude was reduced by protein kinase
A, whereas in the HERG 4M channel these effects were
virtually absent. Because all PKA sites are mutated in the HERG
4M channel, we conclude that PKA produces these
electrophysiological effects by direct phosphorylation of the channel protein.
Regulation of HERG channels by PKA has been found recently in another
expression system as well. Palma et al. (15) could demonstrate that stimulation of PKA reduces HERG currents in
HERG-transfected cultural cells. In isolated guinea pig cardiomyocytes,
the rapid component of the delayed rectifier potassium current,
IKr, that is produced by the HERG potassium
channel was decreased by stimulating protein kinases, presumably PKA
(13). Therefore regulation of HERG channels by PKA may be of
physiological relevance.
The baseline midpoint of the activation curve was In a previous study (13), we demonstrated that the phorbol ester PMA
produces a stronger PKA-dependent shift in the activation kinetics of HERG channels (37 mV) compared with the shift by
Ro-20-1724 (14.0 mV) or forskolin (14.1 mV). PMA is a very potent but
not specific compound. It is known to be an activator of protein kinase C and other protein kinases including PKA, and many of its effects are
not fully understood. There is clear evidence that direct activation of
protein kinase C is not involved in shifting the activation curve of
HERG channels, because the very similar phorbol ester,
phorbol-12,13-didecanoate, known to activate PKC (16), does not produce
any shift (data not shown). Furthermore, experiments with the direct
and very specific PKC activator 1-stearoyl-2-arachidonyl-glycerol support these results as well, because they produced no shift (13). In
this study, we exclusively investigated PKA-specific effects
particularly with PKA pathway-specific compounds, such as forskolin or
Ro-20-1724. Nevertheless there are possibly other factors as well
mediating the PMA-induced shift that cannot be determined at this point.
Some clinical conditions might reflect the physiological significance
of our findings. Under
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
20 °C. Phorbol-12,13-didecanoate (Calbiochem) was dissolved in
Me2SO to a stock solution of 10 mM and stored
at
20 °C. On the day of experiments, aliquots of the stock
solution were diluted to the desired concentration with the bath
solution. All measurements were carried out at room temperature
(20 °C).
3 dB, four-pole Bessel filter) before digitalization at 5-10 kHz.
Recordings were performed using a commercially available amplifier
(Warner OC-725A, Warner Instruments, Hamden, CT) and Pclamp software
(Axon Instruments, Foster City, CA) for data acquisition and analysis.
No leak subtraction was done during the experiments. The recording
chamber was continually perfused. Activation curves were fitted with a
Boltzmann distribution: G(V) = Gmax/(1
exp[(V1/2
V)/k]),
where V is the test pulse potential,
V1/2 is the half-maximal activation potential,
and k is the slope of the activation curve. Statistical data
are expressed as mean ± S.D. (n = number of
experiments performed). We used paired and unpaired Student's
t test to compare the statistical significance of the
results: p < 0.05 was considered to be statistically significant.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (29K):
[in a new window]
Fig. 1.
Hypothetical membrane folding model for the
HERG potassium channel. The amino and carboxyl termini and the six
membrane-spanning domains are indicated. The locations of four putative
PKA-specific phosphorylation sites and mutations generated in this
study are illustrated. For simplicity, only the mutated amino acids are
shown.
80 mV to +80 mV
(increment 10 mV) for 0.4 s and a second step at
120 mV to
measure inward tail currents. The holding potential was
80 mV in all
experiments performed in this study. The tail current amplitude depends
on the preceding test pulse and is a measure of channel activation.
The normalized tail current amplitude was inverted and displayed as a
function of the preceding test pulse potential, which results in the
activation curve. In the control currents, the voltage for half-maximal
activation V1/2 was
4.3 mV (Fig. 2,
A and C). When 100 µM Ro-20-1724
was applied into the bath for 30 min (Fig. 2B), the
activation curve was shifted by 14.0 mV to 9.7 mV (Fig. 2C).
The average shift in five experiments was 12.4 ± 3.2 mV. This was
statistically significant. We used an additional protocol that evokes
outward tail currents as shown in Fig. 2D. The variable test
pulse from
80 to 80 mV (increment 10 mV) for 0.4 s was followed
by a constant return pulse to
60 mV (0.4 s). The control HERG current
had an activation threshold of
40 mV, then the current amplitude
reached a maximum at 0 mV and decreased at test pulse potentials from
20 to 70 mV because of inward rectification that is characteristic to
this channel (3, 5, 14). Typical current traces are shown in Fig.
2D (control measurements) and Fig. 2E (after
application of 100 µM Ro-20-1724 into the bath for 30 min). The maximum outward current amplitude during the test pulse was
reduced significantly by 19.1 ± 12.8% (n = 5).
Fig. 2F displays the current amplitude during the test pulse
as a function of the test pulse potential (control measurement and
after incubation with 100 µM Ro-20-1724 for 30 min).

View larger version (29K):
[in a new window]
Fig. 2.
Stimulation of PKA by the phosphodiesterase
IV inhibitor Ro-20-1724 causes a shift of HERG WT activation curve and
suppression of outward current. Control measurements
(panels A and D) and the effect of 100 µM Ro-20-1724 after 30 min (panels B and E) in the same oocyte. Panel C shows activation curves, i.e. the normalized
inverted peak tail current amplitude as a function of the test pulse
potential during the first step of the inward tail protocol
(panels A and B). Ro-20-1724 shifts
the activation curve by 14.0 mV. Panel F shows the current
amplitude at the end of the test pulse of the outward tail protocol (in
D and E) as a function of the test pulse
potential in control and after stimulation with Ro-20-1724. The
maximum current amplitude at 0 mV is reduced in the measurements with
Ro-20-1724 by 30.3%. Inward tail protocol in panels A and
B: holding potential
80 mV, test pulse
80 to 80 mV (400 ms) in 10 mV increments, return pulse constant
120 mV (400 ms).
Outward tail protocol in panel D and E: holding
potential
80 mV, test pulse
80 to 80 mV (400 ms) in 10 mV
increments, return pulse constant
60 mV (400 ms). Bath: 5 mM K+.
16.4 ± 1.6 mV (n = 6)
(HERG wild type gave
4.7 ± 1.5 mV (n = 3)). In
contrast to HERG WT, addition of 100 µM Ro-20-1724
caused virtually no change of current properties in HERG 4M
after 30 min of perfusion (Fig. 3, D and E).
V1/2 was only shifted by 3.8 ± 1.7 mV to
12.6 ± 2.4 mV (n = 6) (Fig. 3C and
Fig. 6A), and there was no significant current
reduction ((
I = +2.8 ± 8.1% (n = 6) (Fig. 3F)). Thus, direct
phosphorylation of HERG WT channels at its PKA phosphorylation sites is
responsible for the activation shift induced by PKA.

View larger version (30K):
[in a new window]
Fig. 3.
Stimulation of PKA with the phosphodiesterase
inhibitor Ro-20-1724 causes no significant effects in the HERG
4M channel, where all PKA phosphorylation sites
were mutated to nonphosphorylatable alanines. Control measurements
of HERG 4M (panels A and D) and the
effect of 100 µM Ro-20-1724 (panels B and
E) after 30 min in the same oocyte. The shift of the
activation curve was not significant (3.7 mV, panel C), and
there was no current reduction (+1.4%, panel F) due to the
lack of functional PKA phosphorylation sites. Protocols and plots were
identical to those in Fig. 2. Bath: 5 mM
K+.

View larger version (29K):
[in a new window]
Fig. 4.
Forskolin (400 µM), an adenylate cyclase activator that
leads to PKA stimulation, shifts the activation curve in HERG WT
currents. Original currents obtained from the same oocyte before
(panels A and D) and after exposure to 400 µM forskolin (60 min; panels B and
E). The resulting activation curve is shifted by 13.6 mV
(panel C). Maximum outward current amplitude (measured at
the end of the test pulse in panels D and E) was
reduced by 59.0%. Protocols and plots were identical to those shown in
Fig. 2. Bath: 5 mM K+.
16.6 ± 0.4 mV to
12.3 ± 2.1 mV (n = 3, Fig. 5C). This shift was significantly different from
the effect of forskolin on HERG wild type channels. Currents during
test pulses were also reduced but to a smaller extent (
22.3 ± 26.2% (n = 3), Fig. 5, D-F), compared with
HERG wild type (
39.9%). Thus the presence of functional
phosphorylation sites regulates the PKA-mediated activation shift in
HERG channels by forskolin.

View larger version (31K):
[in a new window]
Fig. 5.
Mutation of the PKA phosphorylation sites
inhibits the shift of activation curve by forskolin in the HERG
4M channel. Panels A and D
show typical control measurements of HERG 4M currents in
different protocols. The resulting currents (same oocyte) after
perfusion with 400 µM forskolin (60 min) are shown in
panels B and E. The shift of activation curve by
forskolin was 3.1 mV (panel C), reduction of the current
amplitude at the end of the test pulse was 43.2% (panel F).
Protocols and plots were identical to those shown in Fig. 2. Bath: 5 mM K+.
10.1
mV More Negative Than HERG Wild Type Activation Curves--
Based on
the results described above, it is likely that PKA-mediated
phosphorylation is involved in HERG activation. This hypothesis is
further strengthened by the observation that the baseline midpoint of
the activation curve of HERG 4M was
14.8 ± 2.2 mV
(n = 9), whereas the HERG WT baseline midpoint was
4.7 ± 1.5 mV (n = 3, Fig.
6). This difference of
10.1 mV was
statistically significant. The difference in the activation curves
becomes even greater when we compare the activation curves values under
stimulation of PKA with the phosphodiesterase inhibitor Ro-20-1724.
Under this condition, the HERG 4M has a half-maximal
activation voltage of
12.6 ± 2.4 mV (n = 6),
whereas HERG wild type has 9.7 ± 3.2 mV (n = 5).
This results in a difference of 22.3 mV between HERG 4M and
HERG wild type (Fig. 6A). Some of the clones carrying single mutations showed a tendency toward more negative potentials as well (T895A, S283A, and especially S890A) (Fig. 6B). The
values were V1/2=
5.9 ± 2.4 mV for T895A
(n = 9), V1/2=
6.0 ± 3.0 mV for S283A (n = 6), V1/2=
8.0 ± 4.8 mV for S890A (n = 6), and V1/2=
2.6 ± 1.9 mV for S1137A
(n = 7).

View larger version (20K):
[in a new window]
Fig. 6.
A, activation curves of HERG WT and HERG
4M during control measurements and after incubation with
100 µM Ro-20-1724 for 30 min in a typical experiment.
Inhibition of the phosphodiesterase IV by Ro-20-1724 causes a shift of
the activation curve in HERG WT channels by 14.0 mV, whereas in HERG
4M channels there was no significant shift (3.7 mV). Note
that the baseline activation curve is more negative in HERG
4M than in HERG WT channels. B, graphical
overlay of the channel baseline activation curves of HERG, HERG
4M, and the four single mutations of HERG. Mean values of
control activation curves for each channel type resulting from 3 to 9 oocytes measurements are shown. Symbols represent mean activation
curves for HERG WT (
), HERG S283A (
), HERG S890A (
), HERG
T895A (
), HERG S1137A +, HERG 4M (
).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
4.7 mV for HERG WT
and
14.8 mV for HERG 4M (Fig. 6A). This
difference in the baseline activation curves indicates that the
positions of the mutations and its phosphorylation by PKA are crucial
for activation. Even more so, because the difference in activation after stimulation of PKA was higher (22mV) (Fig. 6A). There
are two possible explanations for the difference in the baseline
half-maximal activation voltage between HERG WT and HERG 4M
channels. Either mutating the serines or threonines to alanines causes
this effect, but more likely the naturally occurring higher
phosphorylation occupancy of HERG WT compared with HERG 4M
induces this baseline shift. All four mutations contribute to the
baseline shift, because single mutations shift the activation curve to
a smaller extent compared with HERG 4M (Fig.
6B).
-adrenergic stimulation (17-19) or in
pathophysiological situations like sepsis (20-23) and ischemia (24),
the cAMP level in cardiac cells is elevated. At the same time these
conditions are associated with a high incidence of cardiac arrhythmias.
Also, patients with congenital long QT syndrome typically develop
"torsade de pointes" arrhythmias under emotional or physical stress
when cAMP levels are elevated (25, 26). Finally arrhythmias are a
common side effect during the therapeutical use of phosphodiesterase
inhibitors (27) in situations like chronic heart failure (28) or
cardiogenic shock. Our results demonstrate a link between the
cAMP-PKA-system and the repolarizing HERG potassium current. The
PKA-induced phosphorylation of HERG and changes in repolarization
described in this study may be a crucial link in arrhythmogenesis.
Thus, this regulatory process may be a pharmacological target for
future therapeutic approaches in antiarrhythmic therapy.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. M. T. Keating for providing the HERG clone, and we gratefully acknowledge the technical support of K. Güth, S. Kadel, and S. Lück.
| |
FOOTNOTES |
|---|
* This work was supported by a grant from the Deutsche Forschungsgemeinschaft project A/11 (to J. K.) within the Sonderforschungsbereich 320 "Herzfunktion und ihre Regulation."The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
These authors contributed equally to this work.
§ To whom correspondence should be addressed. Tel.: 011-49-6221-568855; Fax: 011-49-6221-565515; E-mail: johannkiehn@ukl.uniheidelberg.de.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: IKr, delayed rectifier potassium current; HERG, human ether-a-go-go-related gene; PKA, cyclic AMP-dependent protein kinase; PDE IV, cAMP-specific phosphodiesterase; PMA, phorbol 12-myristate 13-acetate; WT, wild type.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Carmeliet, E. (1993) Eur. Heart J. 14 Suppl. H, 3-13 |
| 2. |
Warmke, J. E.,
and Ganetzky, B.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
3438-3442 |
| 3. | Sanguinetti, M. C., Changan, J., Curran, M. E., and Keating, M. T. (1995) Cell 81, 1-20[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
Trudeau, M. C.,
Warmke, J. W.,
Ganetzky, B.,
and Robertson, G. A.
(1995)
Science
269,
92-95 |
| 5. | Kiehn, J., Lacerda, A. E., Wible, B., and Brown, A. M. (1996) Circulation 94, 2572-2579[Medline] [Order article via Infotrieve] |
| 6. |
Spector, P. S.,
Curran, M. E.,
Keating, M. T.,
and Sanguinetti, M. C.
(1996)
Circ. Res.
78,
499-503 |
| 7. | Kiehn, J., Thomas, D., Karle, C. A., Schöls, W., and Kübler, W. (1999) Naunyn-Schmiedeberg's Arch. Pharmacol. 359, 212-219[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Sanguinetti, M. C.,
Curran, M. E.,
Spector, P. S.,
and Keating, M. T.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
2208-2212 |
| 9. | Roden, D. M., Lazzara, R., Rosen, M., Schwartz, P. J., Towbin, J., and Vincent, G. M. (1996) Circulation 94, 1996-2012[Medline] [Order article via Infotrieve] |
| 10. |
Walsh, K. B.,
and Kass, R. S.
(1988)
Science
242,
67-69 |
| 11. |
Seamon, K. B.,
Padgett, W.,
and Daly, J. W.
(1981)
Proc. Natl. Acad. Sci. U. S. A.
78,
3363-3367 |
| 12. | Beavo, J. A. (1998) Adv. Second Messenger Phosphoprotein Res. 22, 1-38 |
| 13. |
Kiehn, J.,
Karle, C.,
Thomas, D.,
Yao, X.,
Brachmann, J.,
and Kübler, W.
(1998)
J. Biol. Chem.
273,
25285-25291 |
| 14. |
Sanguinetti, M. C.,
and Jurkiewicz, N. K.
(1990)
J. Gen. Physiol.
96,
195-215 |
| 15. | Palma, E., Yu, Z., Fishman, G. I., and McDonald, T. V. (1998) Circulation 98 Suppl. I, 57 |
| 16. | Darbon, J. M., Valette, A., and Bayard, F. (1986) Biochem. Pharmacol. 35, 2683-2686[CrossRef][Medline] [Order article via Infotrieve] |
| 17. |
Sun, Z. H.,
Swan, H.,
Viitasalo, M.,
and Toivonen, L.
(1998)
J. Am. Coll. Cardiol.
31,
1400-1405 |
| 18. | Kang, J. X., and Leaf, A. (1995) Biochem. Biophys. Res. Commun. 208, 629-636[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Lerman, B. B., Belardinelli, L., West, G. A., Berne, R. M., and DiMarco, J. P. (1986) Circulation 74, 270-280[Medline] [Order article via Infotrieve] |
| 20. | Hsu, C., Yang, S. L., Hsu, S. P., Hsu, H. K., and Liu, M. S. (1997) J. Surg. Res. 71, 161-165[CrossRef][Medline] [Order article via Infotrieve] |
| 21. | Bender, J. S. (1996) Am. Surg. 62, 73-75[Medline] [Order article via Infotrieve] |
| 22. | Yang, S. L., Hsu, C., Lue, S. I., Hsu, H. K., and Liu, M. S. (1997) Shock 8, 68-72[Medline] [Order article via Infotrieve] |
| 23. | Varriale, P., and Ramaprasad, S. (1995) J. Electrocardiol. 28, 327-329[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Saman, S., Coetzee, W. A., and Opie, L. H. (1988) J. Mol. Cell. Cardiol. 20, 91-95[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Priori, S. G., Napolitano, C., Paganini, V., Cantu, F., and Schwartz, P. J. (1997) PACE 20, 2052-2057 |
| 26. | Zhou, J. T., Zheng, L. R., and Liu, W. Y. (1992) PACE 15, 2164-2168 |
| 27. | Naccarelli, G. V., and Goldstein, R. A. (1989) Am. J. Cardiol. 63, 35A-40A[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Packer, M. (1989) Am. J. Cardiol. 63, 41A-45A[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
S. L. Cockerill, A. B. Tobin, I. Torrecilla, G. B. Willars, N. B. Standen, and J. S. Mitcheson Modulation of hERG potassium currents in HEK-293 cells by protein kinase C. Evidence for direct phosphorylation of pore forming subunits J. Physiol., June 1, 2007; 581(2): 479 - 493. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Y. M. Yeung and I. A. Greenwood Pharmacological and biophysical isolation of K+ currents encoded by ether-a-go-go-related genes in murine hepatic portal vein smooth muscle cells Am J Physiol Cell Physiol, January 1, 2007; 292(1): C468 - C476. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-u. Choe, E. Schulze-Bahr, A. Neu, J. Xu, Z. I. Zhu, K. Sauter, R. Bahring, S. Priori, P. Guicheney, G. Monnig, et al. C-terminal HERG (LQT2) mutations disrupt IKr channel regulation through 14-3-3{epsilon} Hum. Mol. Genet., October 1, 2006; 15(19): 2888 - 2902. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. N. Obreztchikova, K. W. Patberg, A. N. Plotnikov, N. Ozgen, I. N. Shlapakova, A. V. Rybin, E. A. Sosunov, P. Danilo Jr., E. P. Anyukhovsky, R. B. Robinson, et al. IKr contributes to the altered ventricular repolarization that determines long-term cardiac memory Cardiovasc Res, July 1, 2006; 71(1): 88 - 96. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Allouis, F. Le Bouffant, R. Wilders, D. Peroz, J.-J. Schott, J. Noireaud, H. Le Marec, J. Merot, D. Escande, and I. Baro 14-3-3 Is a Regulator of the Cardiac Voltage-Gated Sodium Channel Nav1.5 Circ. Res., June 23, 2006; 98(12): 1538 - 1546. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gentile, T. Darden, C. Erxleben, C. Romeo, A. Russo, N. Martin, S. Rossie, and D. L. Armstrong Rac GTPase signaling through the PP5 protein phosphatase PNAS, March 28, 2006; 103(13): 5202 - 5206. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhou, C. E. Augelli-Szafran, J. A. Bradley, X. Chen, B. J. Koci, W. A. Volberg, Z. Sun, and J. S. Cordes Novel Potent Human Ether-a-Go-Go-Related Gene (hERG) Potassium Channel Enhancers and Their in Vitro Antiarrhythmic Activity Mol. Pharmacol., September 1, 2005; 68(3): 876 - 884. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Thomas, A.-B. Wimmer, C. A. Karle, M. Licka, M. Alter, M. Khalil, H. E. Ulmer, S. Kathofer, J. Kiehn, H. A. Katus, et al. Dominant-negative IKs suppression by KCNQ1-{Delta}F339 potassium channels linked to Romano-Ward syndrome Cardiovasc Res, August 15, 2005; 67(3): 487 - 497. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Thomas, B. C. Hammerling, A.-B. Wimmer, K. Wu, E. Ficker, Y. A. Kuryshev, D. Scherer, J. Kiehn, H. A. Katus, W. Schoels, et al. Direct block of hERG potassium channels by the protein kinase C inhibitor bisindolylmaleimide I (GF109203X) Cardiovasc Res, December 1, 2004; 64(3): 467 - 476. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-S. Bian, A. Kagan, and T. V. McDonald Molecular analysis of PIP2 regulation of HERG and IKr Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2154 - H2163. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Hirdes, L. F. Horowitz, and B. Hille Muscarinic modulation of erg potassium current J. Physiol., August 15, 2004; 559(1): 67 - 84. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J Paavonen, H. Chapman, P. J Laitinen, H. Fodstad, K. Piippo, H. Swan, L. Toivonen, M. Viitasalo, K. Kontula, and M. Pasternack Functional characterization of the common amino acid 897 polymorphism of the cardiac potassium channel KCNH2 (HERG) Cardiovasc Res, September 1, 2003; 59(3): 603 - 611. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Thomas, W. Zhang, K. Wu, A.-B. Wimmer, B. Gut, G. Wendt-Nordahl, S. Kathofer, V. A.W. Kreye, H. A. Katus, W. Schoels, et al. Regulation of HERG potassium channel activation by protein kinase C independent of direct phosphorylation of the channel protein Cardiovasc Res, July 1, 2003; 59(1): 14 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. CHERUBINI, S. PILLOZZI, G. HOFMANN, O. CROCIANI, L. GUASTI, E. LASTRAIOLI, S. POLVANI, A. MASI, A. BECCHETTI, E. WANKE, et al. HERG K+ Channels and {beta}1 Integrins Interact through the Assembly of a Macromolecular Complex Ann. N.Y. Acad. Sci., November 1, 2002; 973(1): 559 - 561. [Full Text] [PDF] |
||||
![]() |
F. S. Cayabyab and L. C. Schlichter Regulation of an ERG K+ Current by Src Tyrosine Kinase J. Biol. Chem., April 12, 2002; 277(16): 13673 - 13681. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Thomas, B. Gut, G. Wendt-Nordahl, and J. Kiehn The Antidepressant Drug Fluoxetine Is an Inhibitor of Human Ether-A-Go-Go-Related Gene (HERG) Potassium Channels J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 543 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A Karle, E. Zitron, W. Zhang, S. Kathofer, W. Schoels, and J. Kiehn Rapid component IKr of the guinea-pig cardiac delayed rectifier K+ current is inhibited by {beta}1-adrenoreceptor activation, via cAMP/protein kinase A-dependent pathways Cardiovasc Res, February 1, 2002; 53(2): 355 - 362. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A Karle and J. Kiehn An ion channel 'addicted' to ether, alcohol and cocaine: the HERG potassium channel Cardiovasc Res, January 1, 2002; 53(1): 6 - 8. [Full Text] [PDF] |
||||
![]() |
D. Thomas, G. Wendt-Nordahl, K. Röckl, E. Ficker, A. M. Brown, and J. Kiehn High-Affinity Blockade of Human Ether-A-Go-Go-Related Gene Human Cardiac Potassium Channels by the Novel Antiarrhythmic Drug BRL-32872 J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 753 - 761. [Abstract] [Full Text] |
||||
![]() |
J. Bérubé, D. Caouette, and P. Daleau Hydrogen Peroxide Modifies the Kinetics of HERG Channel Expressed in a Mammalian Cell Line J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 96 - 102. [Abstract] [Full Text] |
||||
![]() |
J. W. Y. Chen and R. A. Eatock Major Potassium Conductance in Type I Hair Cells From Rat Semicircular Canals: Characterization and Modulation by Nitric Oxide J Neurophysiol, July 1, 2000; 84(1): 139 - 151. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cui, A. Kagan, D. Qin, J. Mathew, Y. F. Melman, and T. V. McDonald Analysis of the Cyclic Nucleotide Binding Domain of the HERG Potassium Channel and Interactions with KCNE2 J. Biol. Chem., May 11, 2001; 276(20): 17244 - 17251. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Bian, J. Cui, and T. V. McDonald HERG K+ Channel Activity Is Regulated by Changes in Phosphatidyl Inositol 4,5-Bisphosphate Circ. Res., December 7, 2001; 89(12): 1168 - 1176. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||